A blended independent educational program designed by Springer Healthcare IME, in collaboration with the International Hypoglycaemia Study Group (IHSG), for diabetes specialists, primary care physicians, and specialist diabetes nurses involved in the treatment and management of people with diabetes.
Despite advances in treatment, hypoglycemia remains a prevalent complication of diabetes which is often overlooked. Newer insulins and technologies have the potential to reduce the risk of hypoglycemia and its complications. To achieve these benefits, they must be correctly integrated into an individualized treatment regimen, taking patient fears and choice into account.
This program aims to support clinicians in a time of rapidly changing treatment options, providing practical guidance in identifying and managing diabetic hypoglycemia.
Professor Simon Heller introduces new learning activities to strengthen and complement the “Diabetic hypoglycemia: recognizing the under-recognized” program. These are specifically designed to benefit all healthcare professionals involved in the management of people with diabetes.
The new expert-led content includes:
- Interactive eLearning modules covering the appropriate introduction and monitoring of therapy to reduce the risk of hypoglycemia
- Case-focused webinar highlighting and discussing the different risk factors for hypoglycemia and how to manage these, where there is an opportunity to submit your own cases for discussion
Professor Simon Heller
He trained in clinical diabetes at Queen’s Medical Centre, Nottingham and in research at the University of Nottingham and Washington University, St Louis, USA. He was Editor of Diabetic Medicine from 2000-2005. He is currently the National Speciality Lead in Diabetes to the NIHR Clinical Research Network and an NIHR Senior Investigator. He is a former member of Diabetes UK Science and Research Advisory Group, a member of the UK NIHR Programme Grants for Applied Research Panel and chairs the UK Juvenile Diabetes Research Foundation, UK Scientific Advisory Committee.
He chairs the International Hypoglycaemia Study group, an independently funded group of international experts with research and clinical expertise in hypoglycaemia. The group has a remit to reduce the burden of hypoglycemia though educational activities.
He chaired the glucose control group of the ADVANCE trial, is a steering committee member of the EXAMINE trial and was the PI on the REPOSE trial measuring the effectiveness of insulin pumps.
His research interests include the pathophysiological responses to hypoglycemia and hypoglycemia unawareness, the potential contribution and mechanisms of hypoglycemia to cardiovascular mortality, the use of insulin analogues and other technologies to reduce hypoglycemia. He also conducts research concerned with developing programs (including the DAFNE intervention) to encourage more effective diabetes self-management. He has authored over 200 original research articles and reviews.
Full disclosure information
- Advisory Board Member: Eli Lilly, Novo Nordisk, Sanofi Aventis, Takeda, Zealand Pharma, UN-EEG, Boehringer Ingelheim
- Consultant: Eli Lilly, Novo Nordisk
- Speaker’s Bureau: Eli Lilly, Novo Nordisk
Hermelinda C Pedrosa
Medical Doctor and Scientific Coordinator
Research Centre, Endocrinology Unit, Regional Taguatinga Hospital, Secretariat of Health, Brasilia, Brazil
Hermelinda C. Pedrosa is an endocrinologist who graduated at the Federal University of Paraiba State; Residency in Internal Medicine and Specialization in Endocrinology at the Hospital de Base de Brasilia. She also trained in Oxford (UK) under a scholarship from the National Council of Research (CNPq) for a two-year fellowship.
She has served as President of the Diabetes Department of the Brazilian Endocrinology and Metabolism (SBEM, 2019-2020); President of the Brazilian Diabetes Society (SBD, 2018-2019).
Dr Pedrosa has focused her career in teaching at the Medicine Course and Residency Programme; serving as Chair of the Diabetes Education Programme in Brasília (1997-2012) when she implemented many pioneer treatment facilities which included the short- and long-acting insulin analogues dispensing program in 2004 and 2005, which led to a broad free-access program to other states in Brazil; the first free delivery of CIIS in the SUS (Brazilian public health service) which was implemented under her coordination (2008).
Dr Pedrosa has written chapters in national and international books, contributed to various papers and national studies.
Currently, she works as head of the Research Centre of the Endocrinology Unit at the Regional Hospital of Taguatinga (DF); is member of the D-FOOT Advisory Board for SACA; Advisor of Government Relations for the SBD. She has been Principal Investigator for Fiocruz in Biomanguinhos, Rio de Janeiro, since 2018, which is a most respected institution of research in Brazil.
Hermalinda Pedrosa declares financial or non-financial support from Fiocruz – Biomanguinhos, Rio de Janeiro, Urgo Medical, Masters Specialty Pharma, Servier do Brasil, AstraZeneca, Novo Nordisk, Roche.
Elizabeth R Seaquist
Pennock Family Chair in Diabetes Research and Professor of Medicine, University of Minnesota, MN, USA
Elizabeth Seaquist is the Director of the Division of Diabetes, Endocrinology and Metabolism and holds the Pennock Family Chair in Diabetes Research at the University of Minnesota. She is also the Vice Chair for Clinical Affairs in the Department of Medicine and the Associate Dean for Medical Specialties and Primary Care for the Medical School.
As a clinical investigator, Dr Seaquist is interested in hypoglycemia and the complications of diabetes. Her research focuses on the effect of diabetes on brain metabolism, structure, and function. She directs the University of Minnesota sites for the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) study and the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) study.
Dr Seaquist was the site investigator for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. She served as the President of Medicine and Science of the American Diabetes Association in 2014. She has an active clinical practice and is board certified in Internal Medicine and Endocrinology, Diabetes, and Metabolism.
Elizabeth Seaquist declares financial or non-financial support from NIH, JDRF, American Board of Internal Medicine
Metabolic Diseases Research Unit (UIEM), Department of Endocrinology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico
Roopa Mehta is an endocrinologist and researcher in the Department of Endocrinology and Metabolism at the INCMNSZ. She is the director of the lipid clinic and the cardiovascular laboratory in this hospital. She is an associate professor in both pre- and postgraduate endocrinology programs, and is a principal investigator for phase 3 clinical trials.
Dr Mehta undertook her medical training at the United Medical and Dental Schools of Guy’s and St Thomas’ Hospitals, London, UK. She subsequently trained as an endocrinologist at the INCMNSZ. On completing the residency program, Dr Mehta subspecialized in diabetes and metabolism and gained further clinical and investigative experience rotating at the Joslin Diabetes Center, Boston, MA, USA. She holds a masters degree in medical sciences from the National Autonomous University of Mexico and is currently completing her doctorate.
Dr Mehta’s research interests focus on Type 2 diabetes mellitus (clinical investigation), metabolic syndrome and dyslipidemia. She has received the Alfonso Rivera Research Award and the Young Investigator Award from the AACE. Dr Mehta has authored and co-authored publications in international journals in addition to numerous book chapters. She is a co-editor of a book for patients – “Living with Diabetes: A Practical Manual”.
Roopa Mehta declares honoraria and/or consultation fees from Novo Nordisk, Abbott, AstraZeneca, Amgen, Boehringer Ingelheim, Eli Lilly, Sanofi, and Janssen.
Consultant Diabetologist, University Hospitals of Derby and Burton NHS Foundation Trust and Honorary (consultant) Assistant Professor, University of Nottingham, Nottingham, UK
Emma Wilmot’s specialist interests include Type 1 diabetes, insulin pump therapy and diabetes technology, young adults with diabetes and antenatal diabetes care.
Dr Wilmot is chair of the ABCD Diabetes Technology Network UK. In this role she leads the delivery of a program of educational events for multidisciplinary diabetes teams. She has led the development of a suite of national ‘best practice’ guides related to insulin pump therapy and is a member of the National Diabetes Audit Insulin Pump Expert Reference Group, developing the 2018 national Type 1 diabetes service level audit. Dr Wilmot has been involved in the #language matters movement which aims to improve healthcare professional communication with people with diabetes.
Dr Wilmot was awarded the University of Leicester medal for excellent PhD performance in 2013 for her PhD “Type 2 diabetes in younger adults”.
Personal fees from Abbott Diabetes Care, Dexcom, Diasend, Eli Lilly, Medtronic, Novo Nordisk, Sanofi Aventis.
Professor of Primary Care Diabetes and Vascular Medicine, University of Leicester, UK
Kamlesh Khunti is Co-Director of the Leicester Diabetes Centre and leads a research group that is currently working on the early identification of, and interventions with, people who have diabetes or are at increased risk of developing diabetes. His work has influenced national and international guidelines on the screening and management of people with diabetes. Professor Khunti is also Director of the UK National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East Midlands and Director of The Real World Evidence Unit. He is a NIHR Senior Investigator and Principal Investigator on several major national and international studies. He has published over 650 articles.
Professor Khunti is a Fellow of the Academy of Medical Sciences and is currently an advisor to the Department of Health, a Clinical Advisor for the National Institute for Health and Care Excellence (NICE) and Secretary of the Primary Care Study Group of the European Association for the Study of Diabetes. He is Past Chair of the Department of Health–RCGP Committee on Classification of Diabetes and is Past Chair of the NICE Guidelines on Prevention of Diabetes. In addition, he is Co-Director of the Diabetes MSc at Leicester University. He has won numerous awards nationally and internationally.
Grants/Research Support: AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme.
Test your knowledge with two interactive activities authored by international diabetes experts:
- Initial introduction of therapy, looking at the most appropriate and individualized treatment plans to avoid the risk of hypoglycemia.
- Monitoring and follow-up, focusing on continuous glucose monitoring (CGM) data interpretation and treatment inertia.
Guided by diabetes specialists, choose and explore different treatment paths by introducing new insulins and technologies.
Faculty: Professor Timothy Jones (Australia), Dr Emma Wilmot (UK)
Test yourself with three expert-authored case studies involving patients presenting with hypoglycemia complications. What treatment advice would you give them?
Faculty: Professor Kamlesh Khunti (UK), Dr Yingying Luo (China), Professor Ulrik Pedersen-Bjergaard (Denmark)
Watch hypothetical patient–doctor consultations covering patient fears and how to manage them. Learn with practical advice given by clinicians as they offer commentary and insights throughout the workshop.
Faculty: Professor Stephanie Amiel (UK), Professor Simon Heller (UK), Dr Emma Wilmot (UK)
After participating in the program, learners will be able to:
- Describe new insulins and combinations which can control the risk of hypoglycemia and improve adherence
- Apply best practice for monitoring patients (including importance of time in range) and interpreting CGM data to ensure treatment inertia does not occur
- Debate how to recognize and manage patients with different risk profiles for hypoglycemia
Continuing Medical Education
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.
NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NACCME designates AMA PRA Category Credit(s)™ for the following activities:
Completion of each eLearning AMA PRA Category 0.25 Credits™
Attendance at Webinar AMA PRA Category 1.0 Credits™
The case studies and workshops are no longer open for accreditation but will continue to be available for participation.
How To Claim Your Credits
To claim your credits for participating in the accredited activities, you will need to complete the activity then fill out the short evaluation form at the end of each module.
During completion of the evaluation form, you can select the box that indicates accreditation is required.
Use of Proprietary Names
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
Unapproved and/or Investigational Uses of Drugs and Devices
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.
The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
Disclosure of Relevant Financial Relationships
NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.
NACCME requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
In addition to the speaker faculty, NACCME and Springer Healthcare IME planners and staff include Greaton Sellers, Jules Morgan, and Rebecca Cox. Greaton Sellers, Jules Morgan, and Rebecca Cox have no financial or otherwise interests to disclose.
North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof.
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and its joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2020 Springer Healthcare IME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Springer Healthcare IME.
This independent resource is brought to you in collaboration with the International Hypoglycaemia Study Group (IHSG).